cancer vaccines
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
... most cancer vaccine trial designs due to the disease-specificity of the ...to cancer vaccines or other immunotherapeutic agents because the absence of tumor shrinkage may not be reflective of the ...
15
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
... expressing cancer-associated antigens? First, all the vaccine-targeted antigens (CEA, PSA, or 5 T4) represent non-mutated se- quences, which have typically exhibited low immunogen- icity, linked to weak immune ...
21
Cancer vaccines: a newer front of immunotherapy
... of cancer and are therefore an attractive therapeutic target for cancer ...with vaccines used to treat and prevent infectious diseases caused by viruses have provided a platform for identifying ...
5
RECENT ADVANCES IN CANCER VACCINES: AN OVERVIEW
... of cancer vaccines is currently in an active state of clinical ...virus vaccines namely Gardasil and Cervarix have been approved as a prophylactic cancer ...kidney cancer; has been ...
6
Recent advances in the development of breast cancer vaccines
... Second, the main barrier against vaccination is probably due to complex immuno-escaping mechanisms developed by cancer cells. Regulatory cells such as T-Regs and molecular immune checkpoints (eg, CTLA-4, PD1/PD1L) ...
10
Immune System Regulation With Cancer Vaccines Based on Dendritic Cells
... cancer vaccines, adoptive cell transfer, tumor infecting viruses, checkpoint inhibitors, cytokines and ...adjuvants. Cancer immunobiology provides the chance to develop our immune system to eradicate ...
9
Imaging activated T cells predicts response to cancer vaccines
... situ cancer vaccines are under active clinical investigation, given their reported ability to eradicate both local and disseminated ...clinical cancer immunotherapy ...
13
Cyclooxygenase Inhibition in Cancer Immunotherapy: Combination of Indomethacin with Cancer Vaccines Is Not Always Beneficial
... of cancer vaccines have been combined with COX-2 inhibitors, assuming that its particular mechanism of action will not influence the overall results of the ...of cancer vaccine and the outcome of the ...
22
Tumor-induced immune suppression of therapeutic cancer vaccines
... treat cancer, but these have not been effective clinically as a result of the difficulty with initiating and maintaining antigen-specific responses to self-antigens present on tumor ...
182
Cancer vaccines: progress reveals new complexities
... a cancer vaccine in hand that can reliably increase patient survival or induce tumor ...therapeutic cancer vaccines has proven to be an enormous challenge, and many of the strategies learned in the ...
7
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
... new cancer vaccines have recently shown promise in prolonging patient ...the vaccines themselves as well as combinatorial application of vaccines with agents that target the tumor ...
16
Translating Tumor Antigens into Cancer Vaccines
... of cancer, the concept of immunizing with whole tumor cells to avoid the exclusion of potentially relevant antigens from the vaccine is still ...a cancer vaccine has been tested in several clinical trials ...
12
Therapeutic cancer vaccines
... responses. Cancer vaccines with such high-performance capacity are RNA, DNA, and SLP vaccines with the appropriate added or built-in ...into cancer vaccines is of cru- cial importance, ...
13
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
... Therapeutic cancer vaccines, however, have not yet made a major impact, but are starting to reach clinical practice now that the platforms are optimized and tumor-specific antigens are ...that cancer ...
41
Aging, cancer, and cancer vaccines
... of cancer vaccines also should be widely encouraged ...elderly cancer patients is weakened by age-related changes and usually by the immunosup- pressive effects of conventional treatments: this ...
11
Adjuvants for peptide-based cancer vaccines
... localization, and survival of vaccination-induced, tumor- specific T cells [10]. However, extremely short antigen presentation (such as after injection of minimal epitope peptides in saline), especially in the absence of ...
11
Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines
... anti-cancer vaccines may be optimized by making use of the particle bom- bardment technology as a systematic, highly effective and multiple site-delivery mode for the pretreatment of tumor-bearing mice ...
15
Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
... peptide vaccines in sarcoma and fibrosarcoma tumor ...pancreatic cancer patients and immune responses against viral-like neoantigens ...(NAM) vaccines delivered by DNA-EP in murine tumor models and ...
13
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
... peutic vaccines is most likely due to the large number of known melanoma antigens and the natural antigenicity of melanomas (reviewed in ...therapeutic vaccines for the treatment of melanoma ...
12
The perfect personalized cancer therapy: cancer vaccines against neoantigens
... It is clear that a single therapeutic approach will not win the battle against a complex and evolving system such as Cancer. Intrinsic factors such as BRAF mutations are as- sociated with a reduced frequency of ...
10